Skip to main content
. Author manuscript; available in PMC: 2019 May 31.
Published in final edited form as: Transl Res. 2017 Feb 4;184:12–20.e1. doi: 10.1016/j.trsl.2017.01.003

Figure 2. Procoagulant EVs quantified by a functional prothrombinase- and a EV-associated TF activity assay.

Figure 2

(A) PS exposure on EVs determined with a prothrombinase assay was significantly higher in AF (n=10) compared with plasma from healthy controls (n=7). (B) EV-TF activity determined with a factor Xa generation assay was significantly higher in AF (n=10) compared with plasma from cancer patients with overt DIC (n=10). EV-TF activity was not detectable in plasma from healthy controls (n=7). Measurements were performed in duplicates. EV, extracellular vesicles; TF, tissue factor; PS, phosphatidylserine; AF, amniotic fluid; DIC, disseminated intravascular coagulation.